Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as immunology products to treat Alzheimer's disease. In addition, it offers oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine. Further, the company provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; Nektar Therapeutics; NextCure, Inc.; and Dicerna Pharmaceuticals, Inc., as well as has strategic collaboration with Sigilon Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone317-276-2000
Debt
Current Ratio1.91
Quick Ratio1.53
Price-To-Earnings
Sales & Book Value
Annual Sales$22.87 billion
Price / Sales5.42
Price / Cash Flow20.98
Price / Book11.05
Profitability
Net Income$-204,100,000.00
Net Margins1.85%
Return on Assets12.64%
Miscellaneous
Employees40,655
OptionableOptionable
Eli Lilly And Co (NYSE:LLY) Frequently Asked Questions
What is Eli Lilly And Co's stock symbol?
Eli Lilly And Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."
How often does Eli Lilly And Co pay dividends? What is the dividend yield for Eli Lilly And Co?
Eli Lilly And Co announced a quarterly dividend on Wednesday, December 19th. Investors of record on Friday, February 15th will be given a dividend of $0.645 per share on Friday, March 8th. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.20%. The ex-dividend date of this dividend is Thursday, February 14th. This is a positive change from Eli Lilly And Co's previous quarterly dividend of $0.56. View Eli Lilly And Co's Dividend History.
How were Eli Lilly And Co's earnings last quarter?
Eli Lilly And Co (NYSE:LLY) posted its quarterly earnings data on Tuesday, November, 6th. The company reported $1.39 EPS for the quarter, beating the Zacks' consensus estimate of $1.35 by $0.04. The firm had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. Eli Lilly And Co had a return on equity of 42.84% and a net margin of 1.85%. The firm's revenue for the quarter was up 7.1% compared to the same quarter last year. During the same period last year, the firm earned $1.05 earnings per share. View Eli Lilly And Co's Earnings History.
When is Eli Lilly And Co's next earnings date?
How can I listen to Eli Lilly And Co's earnings call?
Eli Lilly And Co will be holding an earnings conference call on Wednesday, February 13th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.
What guidance has Eli Lilly And Co issued on next quarter's earnings?
Eli Lilly And Co updated its FY19 earnings guidance on Wednesday, December, 19th. The company provided earnings per share guidance of $5.90-6.00 for the period, compared to the Thomson Reuters consensus estimate of $5.77. The company issued revenue guidance of $25.3-25.8 billion, compared to the consensus revenue estimate of $24.57 billion.Eli Lilly And Co also updated its FY18 guidance to $5.55-5.60 EPS.
What price target have analysts set for LLY?
19 analysts have issued 12-month price objectives for Eli Lilly And Co's shares. Their forecasts range from $86.00 to $132.00. On average, they anticipate Eli Lilly And Co's stock price to reach $110.9333 in the next twelve months. This suggests that the stock has a possible downside of 5.3%. View Analyst Price Targets for Eli Lilly And Co.
What is the consensus analysts' recommendation for Eli Lilly And Co?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly And Co in the last year. There are currently 9 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eli Lilly And Co.
What are Wall Street analysts saying about Eli Lilly And Co stock?
Here are some recent quotes from research analysts about Eli Lilly And Co stock:
- 1. According to Zacks Investment Research, "Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance, Lartruvo and Verzenio are expected to drive revenues. Lilly has launched 10 medicines over the past five years, most of which are successful and are expected to account for 45% of Lilly’s pharmaceuticals sales in 2019. The newly launched CGRP antibody, Emgality could emerge as a significant contributor to long-term growth. Lilly is also having a strong year in terms of its pipeline with several positive late-stage data readouts and regulatory nods. It has also added promising new assets through business development deals. The stock has also outperformed the industry this year so far. However, competitive pressure on Lilly’s drugs is expected to rise in 2019. Challenges remain for the company in the form of generic competition for several drugs including Cialis and rising pricing pressure in the diabetes franchise." (12/31/2018)
- 2. BMO Capital Markets analysts commented, "SIEN continues to execute in 2018; miraDry has reported three consecutive quarters of revenue that exceeded both our estimates and consensus. However, a six-month delay to the Vesta supply ramp leads us to shift our expectations for breast implant expansion toward 2H19. We believe SIEN’s long-term upside and current valuation provide investors with an opportunity to enter the stock at a price well below our 12-month target. Thus, we are upgrading our rating to and introducing a $20 PT." (12/19/2018)
- 3. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and raise our 12-month PT for LLY shares to $128 from $110. The increase in our PT is driven by multiple expansion. We think this is deserved because continued sales growth, margin expansion, and pipeline advancements are still underappreciated, in our opinion." (10/17/2018)
Has Eli Lilly And Co been receiving favorable news coverage?
Headlines about LLY stock have been trending somewhat positive recently, InfoTrie reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eli Lilly And Co earned a news sentiment score of 1.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Eli Lilly And Co's key competitors?
Some companies that are related to Eli Lilly And Co include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG) and Shire (SHPG).
Who are Eli Lilly And Co's key executives?
Eli Lilly And Co's management team includes the folowing people:
- Mr. David A. Ricks, Chairman, CEO & Pres (Age 50)
- Mr. Michael J. Harrington, Sr. VP & Gen. Counsel (Age 55)
- Mr. Enrique A. Conterno, Sr. VP (Age 51)
- Mr. Joshua L. Smiley, Sr. VP & CFO (Age 48)
- Mr. Donald A. Zakrowski, Chief Accounting Officer & VP of Fin.
Who are Eli Lilly And Co's major shareholders?
Eli Lilly And Co's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Lilly Endowment Inc. (11.14%), Atalanta Sosnoff Capital LLC (0.05%), Hexavest Inc. (0.05%), Gateway Investment Advisers LLC (0.05%), Retirement Systems of Alabama (0.05%) and RNC Capital Management LLC (0.04%). Company insiders that own Eli Lilly And Co stock include Alfonso G Zulueta, Christi Shaw, Daniel Skovronsky, Derica W Rice, Donald A Zakrowski, Eli & Co Lilly, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington, Myles O'neill and Susan Mahony. View Institutional Ownership Trends for Eli Lilly And Co.
Which institutional investors are selling Eli Lilly And Co stock?
LLY stock was sold by a variety of institutional investors in the last quarter, including Lilly Endowment Inc., DNB Asset Management AS, Gulf International Bank UK Ltd, Hexavest Inc., Park National Corp OH, Vigilant Capital Management LLC, XR Securities LLC and Louisiana State Employees Retirement System. Company insiders that have sold Eli Lilly And Co company stock in the last year include Alfonso G Zulueta, Christi Shaw, Donald A Zakrowski, Eli & Co Lilly, Enrique A Conterno, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Myles O'neill and Susan Mahony. View Insider Buying and Selling for Eli Lilly And Co.
Which institutional investors are buying Eli Lilly And Co stock?
LLY stock was acquired by a variety of institutional investors in the last quarter, including Atalanta Sosnoff Capital LLC, Pennsylvania Trust Co, Kessler Investment Group LLC, Verde Servicos Internacionais S.A., Monument Capital Management, Chesley Taft & Associates LLC, Dorsey Wright & Associates and TrimTabs Asset Management LLC. Company insiders that have bought Eli Lilly And Co stock in the last two years include Daniel Skovronsky and Jackson P Tai. View Insider Buying and Selling for Eli Lilly And Co.
How do I buy shares of Eli Lilly And Co?
Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eli Lilly And Co's stock price today?
One share of LLY stock can currently be purchased for approximately $117.09.
How big of a company is Eli Lilly And Co?
Eli Lilly And Co has a market capitalization of $123.07 billion and generates $22.87 billion in revenue each year. The company earns $-204,100,000.00 in net income (profit) each year or $4.28 on an earnings per share basis. Eli Lilly And Co employs 40,655 workers across the globe.
What is Eli Lilly And Co's official website?
How can I contact Eli Lilly And Co?
Eli Lilly And Co's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]
MarketBeat Community Rating for Eli Lilly And Co (NYSE LLY)
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly And Co and other stocks. Vote "Outperform" if you believe LLY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LLY will underperform the S&P 500 over the long term. You may vote once every thirty days.
